Replies to post #252540 on Biotech Values

[DewDiligence]

OPT—One interesting component...is that the wAMD type that they are targeting is 'Asian' enriched...

I presume the clinical-trial enrichment you're referring to is for polypoidal choroidal vasculopathy (PCV). There is some controversy over whether PCV is a subtype of AMD or a wholly distinct disease.